|This document has been retired and replaced by "2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation."|
This guideline update states that dabigatran, a new antithrombotic agent that was recently approved by the U.S. Food and Drug Administration, is an alternative to warfarin to help prevent dangerous blood clots in patients with atrial fibrillation. The update is a joint publication of the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the Heart Rhythm Society (HRS).
This focused update—published in the March 2011 issue of HeartRhythm as well as in Circulation and the Journal of the American College of Cardiology—specifically updates the section on emerging antithrombotic agents in the atrial fibrillation treatment guidelines and focuses on the use of dabigatran.
This focused update is not intended to represent an update based on a full literature review from the date of the previous guideline publication. Please consult the "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation—Executive Summary" for policy on clinical areas not covered by the focused update. With the exception of the recommendations presented in this document, the 2006 guideline remains current. Only the recommendations from the affected section(s) of the full-text guideline are included in this focused update.